Newsletters of 2013
Date Newsletter title Download

1 - 2013
  • Vastarel--Removal of indications for ENT and Ophthalmology
  • Ondansetron (Zofran®) -- Restriction of maximum dose to 16 mg instead of 32 mg
  • Novalgin—Technical Committee decision
  • Paracetamol New guidance on treating paracetamol overdose with intravenous acetylcysteine

2 - 2013
  • The Technical Committee -- Withdrawal of ATP from all registered products in Egypt
  • The Technical Committee --  Not receiving registration applications for new products containing meprobamate (as a single ingredient).
  • FDA approves Lucentis to treat diabetic macular edema
  • Over-The-Counter Eye Drops and Nasal Sprays-- Serious adverse events from accidental ingestion by children

3 - 2013
  • Requirements of the Egyptian Display of RMP for immnunosppressive drugs
  • Domperidone-- Serious ventricular arrhythmias and sudden cardiac death
  • Varenicline Updated safety review on the risk of cardiovascular adverse events

4 - 2013
  • EPVC announces the establishment of our first Regional center in Alex
  • FDA approves Invokana to treat type 2 diabetes
  • European Medicines Agency update on Diane 35 and generics used in the treatment of acne
  • Zolpidem containing products-- Lower recommended doses required

5 - 2013
  • A case of death in Egypt after the administration of Rabies vaccine: case report
  • Withdrawal of pharmaceutical products containing "Diosmin" 150mg in Egypt
  • Azithromycin and the risk of potentially fatal heart rhythms

6 - 2013
  • Important new restrictions concerning calcitonin (injection and nasal spray) 
  • Case of "Red Man Syndrome" in a Child received Vancomycin in Alexandria
  • Cinacalcet – DHPC distributed in Egypy concerning cautions against use in children

7 - 2013
  • Case of "Red Man Syndrome" in a Child received Vancomycin in Alexandria
  • New restrictions on use of pharmaceutical products containing Propylene Glycol (PG) 
  • A second case of death in Egypt after the administration of Rabies vaccine: case report.

8 - 2013
  • The Technical Committee – New warning for the veterinary products containing Sulphaquinoxaline 
  • Hydroxyethyl starch (HES)-containing solutions – DHPC distributed in Egypy concerning potential safety signal
  • FDA approves Nymalize-- first nimodipine oral solution for use in certain brain hemorrhage patients

9 - 2013
  • Withdrawal & Recall of Syrups Containing Pizotifen
  • Case of Rash & Convulsion In achild recieved Cortiplex® B6 Pediatric amp by intravenous (IV) injection in Alexandria 
  • FDA approves new drug to treat HIV infection

10 - 2013
  • A Case of Perineal Pain in a woman received Dexamethasone Sodium Phosphate Intravenous (IV) injection in Alexandria
  • Ambroxol Hydrochloride (HCl) solution for injection - compatibility study confirm the degradation of Ambroxol after mixing with commercially available glucose 5 % solution
  • FDA approves Abraxane for late-stage pancreatic cancer

11 - 2013
  • EPVC announces the establishment of our Regional center in Cairo
  • Tetrazepam – Increased risk of Skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS syndrome)
  • Perineal pain as an adverse drug reaction to the dexamethasone
  • Propofol – Risk of Fetal Respiratory Depression due to administration in labor and delivery, including Cesarean section deliveries
  • Egyptian Ministry of Health (MOH) – Egyptian manufactured drugs is as effective as Imported Drugs

12 - 2013
  • Dextromethorphan Hydrobromide - Detection, Quarantine & Execution of Contaminated batches with Levomethorphan in Egypt
  • Hydroxyethyl Starch (HES) - Restricted Patient Population
  • Harvard Business Review - Product related warnings may increase product sales rather than reducing it.